Literature DB >> 8703858

High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration.

N Morlet1, S Young, D Naidoo, G Graham, M T Coroneo.   

Abstract

BACKGROUND: Although intravitreal high dose ganciclovir has previously been found to provide excellent control of cytomegalovirus (CMV) retinitis, little was known about the vitreous concentrations of ganciclovir after a 2 mg intravitreal injection.
METHODS: Eleven vitreous samples were taken from seven patients with CMV retinitis at 24 and 72 hours after a 2 mg intravitreal injection of ganciclovir and the concentration of ganciclovir was measured by high performance liquid chromatography.
RESULTS: The mean concentration of ganciclovir at 24 hours was 143.8 mg/l (95% confidence interval 97.8-190) and at 72 hours was 23.4 mg/l (95% CI 0-49.7). The half life ranged from 11.9 to 26.3 (mean 18.8) hours in the four patients who had two samples taken. The mean half life calculated from the mean concentrations at 24 and 72 hours was 18.3 hours, so the calculated mean concentration at 7 days was 0.6 mg/l.
CONCLUSIONS: This suggests that it takes about 7 days to eliminate the intravitreal ganciclovir, and that it is not likely to accumulate with weekly injections. The intravitreal concentrations achieved with high dose therapy remained above the ID50 for CMV (0.25-1.22 mg/l) for up to 7 days.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703858      PMCID: PMC505431          DOI: 10.1136/bjo.80.3.214

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

1.  Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy.

Authors:  M H Heinemann
Journal:  Arch Ophthalmol       Date:  1989-12

2.  Treatment of cytomegalovirus retinopathy with ganciclovir.

Authors:  G N Holland; Y Sidikaro; A E Kreiger; D Hardy; M J Sakamoto; L M Frenkel; D J Winston; M S Gottlieb; Y J Bryson; R E Champlin
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

3.  Cytomegalovirus retinitis and response to therapy with ganciclovir.

Authors:  D E Henderly; W R Freeman; D M Causey; N A Rao
Journal:  Ophthalmology       Date:  1987-04       Impact factor: 12.079

4.  Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS.

Authors:  K Henry; H Cantrill; C Fletcher; B J Chinnock; H H Balfour
Journal:  Am J Ophthalmol       Date:  1987-01-15       Impact factor: 5.258

5.  Intraocular penetration of new antiviral agent, hydroxyacyclovir (BW-B759U).

Authors:  J Schulman; G A Peyman; M B Horton; J Liu; J C Barber; R Fiscella; P de Miranda
Journal:  Jpn J Ophthalmol       Date:  1986       Impact factor: 2.447

6.  Cytomegalovirus retinitis and acquired immunodeficiency syndrome.

Authors:  D A Jabs; C Enger; J G Bartlett
Journal:  Arch Ophthalmol       Date:  1989-01

7.  Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis.

Authors:  F M Ussery; S R Gibson; R H Conklin; D F Piot; E W Stool; A J Conklin
Journal:  Ophthalmology       Date:  1988-05       Impact factor: 12.079

8.  Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression.

Authors:  G L Daikos; J Pulido; S B Kathpalia; G G Jackson
Journal:  Br J Ophthalmol       Date:  1988-07       Impact factor: 4.638

9.  Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome.

Authors:  J G Gross; S A Bozzette; W C Mathews; S A Spector; I S Abramson; J A McCutchan; T Mendez; D Munguia; W R Freeman
Journal:  Ophthalmology       Date:  1990-05       Impact factor: 12.079

10.  Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results.

Authors:  H L Cantrill; K Henry; N H Melroe; W H Knobloch; R C Ramsay; H H Balfour
Journal:  Ophthalmology       Date:  1989-03       Impact factor: 12.079

View more
  10 in total

Review 1.  A New Vision for the Eye: Unmet Ocular Drug Delivery Needs.

Authors:  Hongwen M Rivers; Siladitya Ray Chaudhuri; Jaymin C Shah; Sachin Mittal
Journal:  Pharm Res       Date:  2015-06-09       Impact factor: 4.200

2.  Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis.

Authors:  Lingyun Cheng; James R Beadle; Ajay Tammewar; Karl Y Hostetler; Carl Hoh; William R Freeman
Journal:  J Ocul Pharmacol Ther       Date:  2011-02-25       Impact factor: 2.671

3.  Trabeculectomy ab interno (trabectome): yet another possibility in the treatment of uncontrolled glaucomatocyclitic crisis under systemic valganciclovir therapy?

Authors:  M Pahlitzsch; N Torun; J Gonnermann; A K B Maier; U Pleyer; E Bertelmann; A Joussen; M K J Klamann
Journal:  Eye (Lond)       Date:  2015-07-03       Impact factor: 3.775

4.  Long-term oral therapy with valganciclovir in patients with Posner-Schlossman syndrome.

Authors:  B Sobolewska; C Deuter; D Doycheva; M Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-28       Impact factor: 3.117

5.  Continued decline of aqueous interleukin-8 after multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis.

Authors:  Bin Wang; Bei Tian; Yong Tao; Jing Hou; Xiao-Tao Zhao; Xiao-Xin Li
Journal:  J Ocul Pharmacol Ther       Date:  2014-05-29       Impact factor: 2.671

6.  High Throughput Screening of Valganciclovir in Acidic Microenvironments of Polyester Thin Films.

Authors:  Teilo Schaller; Tobias Wenner; Rupesh Agrawal; Stephen Teoh; Li Ting Phua; Joachim S C Loo; Terry W J Steele
Journal:  Materials (Basel)       Date:  2015-04-13       Impact factor: 3.623

Review 7.  A Review of Antimicrobial Therapy for Infectious Uveitis of the Posterior Segment.

Authors:  Ahmed B Sallam; Kyle A Kirkland; Richard Barry; Mohamed Kamel Soliman; Tayyeba K Ali; Sue Lightman
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018

8.  Continuous High-Dose (6 mg) vs. Low-Dose (3 mg) Intravitreal Ganciclovir for Cytomegalovirus Retinitis After Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized Controlled Study.

Authors:  Wei-Bin Chen; Ze Long; Jing Hou; Heng Miao; Ming-Wei Zhao
Journal:  Front Med (Lausanne)       Date:  2021-12-24

9.  Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: A pilot study.

Authors:  Samanthila Waduthantri; Lei Zhou; Soon-Phaik Chee
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

Review 10.  The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.

Authors:  Lixiang Wang; Mikael Ben Zhou; Hui Zhang
Journal:  Ophthalmol Ther       Date:  2021-07-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.